GEORGE G. JACKSON, M.D.; THOMAS H. HAIGHT, M.D.; EDWARD H. KASS, Ph.D., M.D.; C. RAY WOMACK, M.D.; THOMAS M. GOCKE, M.D.; MAXWELL FINLAND, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The wide variety of bacterial and other microbial agents which may be implicated in the causation of acute pulmonary infections makes such infections particularly suitable for treatment with the so-called broad spectrum antibiotics. When aureomycin, the first significant agent of this group, became available, detailed clinical and laboratory studies were carried out in this clinic in an attempt to evaluate its efficacy in pneumonias due to various etiologic agents. The results1-4 indicated that this antibiotic was highly effective in the treatment of the various types of cases in which it was used. The present paper deals with similar studies in
JACKSON GG, HAIGHT TH, KASS EH, et al. TERRAMYCIN THERAPY OF PNEUMONIA: CLINICAL AND BACTERIOLOGIC STUDIES IN 91 CASES1. Ann Intern Med. 1951;35:1175–1202. doi: 10.7326/0003-4819-35-6-1175
Download citation file:
© 2019
Published: Ann Intern Med. 1951;35(6):1175-1202.
DOI: 10.7326/0003-4819-35-6-1175
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by: